



Improving lives through the prevention and
treatment of anogenital & HPV-related diseases

ASCCP Board Meeting
Conducted via Zoom
January 17, 2023

Summary

- Dr. Lisa Flowers reviewed the staff project update regarding membership, social media outreach, current programs and projects, updates on the journal, the 2023 Scientific Meeting, and issues related to governance.
- Dr. Francisco Garcia reviewed the financial statement that reflected that the society remains in a healthy financial position and Ms. Rebecca Boland indicated that the audit for the year ending 9/30/22 was currently underway with draft statements under review.
- Dr. Garcia noted the goal for the enduring guidelines group to have a near-final product to present at the 2023 meeting in Houston.
- Ms. Cari Price highlighted issues with the listserv regarding misinformation and arguments among users. Dr. Flowers asked staff to compile examples of these issues on the listserv for the EC to review, assess, and bring back to the board with a recommendation.
- Dr. Flowers walked through the objectives derived from the strategic planning meeting, along with timelines, budget, and responsible parties assigned to each.
- Dr. Flowers noted that Anna-Barbara Moscicki will lead the charge on the update to the paper on cervical cancer screening in immunocompromised patients.
- Dr. Flowers reviewed responses to the USPSTF Anal Cancer Screening Draft Research Plan devised by her and other board members who served as investigators on the ANCHOR trial. The responses were reviewed and approved by the EC and submitted by ASCCP staff.
- The next board meeting will take place in person on Thursday, May 4, 2023 from 7:30 am-12:30 pm at the Marriott Marquis Houston in Houston, TX.

Full Minutes

I CALL TO ORDER

Dr. Lisa Flowers called to order the meeting of the Board at 7:02 pm ET.

II ATTENDANCE

The following persons were present: Patty Cason, David Chelmow, Christine Conageski, Levi Downs, Mark Einstein, Lisa Flowers, Francisco Garcia, Michelle Khan, Lindsay Kuroki, Erin Nelson, Akiva Novetsky, Peter Schnatz, Elizabeth Stier, and Amy Wisner

Staff: Kerry O. Curtis, Cari Price

Guests: Rebecca Boland and Kemal Cankaya

III DISCLOSURE STATEMENT

Dr. Flowers read the disclosure statement included in the meeting agenda.

IV APPROVAL OF MINUTES

Dr. David Chelmow made a motion to approve the minutes from the October 14, 2022, meeting and Dr. Akiva Novetsky seconded the motion. The motion passed unanimously.

V PRESIDENT'S REPORT

Dr. Flowers reviewed the Staff Project Update, found on pp. 11-13 in the Board book. Refer to the board book for details on membership, social media outreach, current programs and projects, updates on the journal, the 2023 Scientific Meeting, and issues related to governance (e.g. bylaws, financial reserves policy). Dr. Flowers thanked Ms. Kerry Curtis and Ms. Cari Price for their work and commended the executive committee for their suggestions and contributions.

TREASURER'S REPORT

Dr. Francisco Garcia referred the board to the financial statement on page 14 of the board book reflecting the two months ended November 30, 2022. He noted that total cash amounted to approximately \$1.5 million, including just over \$300,000 in the operating account and \$1.2 million in short-term investments. Investments amounted to \$5.16 million, reflecting a decrease of \$836,000 due to the vicissitudes of the market. Total assets, he noted, amounted to \$6.9 million with current liabilities of \$578,000, with about half of this figure due to deferred registrations, dues, and exhibit income relating to future meetings that will be recognized at a later date. Overall, Dr. Garcia stated, the society remains in a healthy financial position.

Ms. Rebecca Boland added that the society stood in a better financial position than at the end of the previous fiscal year and indicated that the audit for the year ending 9/30/22 was currently underway with draft statements under review.

Ms. Boland and Mr. Kemal Cankaya left the meeting.

VI OLD BUSINESS

a. Enduring Management Guidelines Updates

Dr. Garcia noted board members received an email outlining a timeline for the enduring guidelines group, noting the goal to have a near-final product to present at the 2023 meeting in Houston. He indicated that larger working groups meetings would take place in late January and early February to review and finalize the language around recommendations with a goal of including feedback from all institutional partners to ensure all partners feel ownership. The recommendations will be presented to the large overarching group on April 23 followed by a

second meeting for the voting process. Dr. Garcia reiterated his estimation that these recommendations should be finalized in time to present at the meeting in Houston.

b. Listserv

Ms. Price opened discussion of the listserv, noting the original intent to moderate bad behavior but not content. She highlighted recent concerns from the practice committee regarding listserv responses that don't follow the guidelines and offer incorrect information. While the listserv includes disclaimers that responses reflect member-to-member communication, Ms. Price noted the impression among users that the information comes directly from ASCCP and asked the board for their thoughts on the issue.

Dr. Mark Einstein offered some history on the listserv, noting that, several years back, a handful of members answered listserv questions to ensure accuracy but the task ultimately became unwieldy. While the practice committee was then tasked to oversee content, some committee members also offered responses that didn't follow guidelines, and thus it was decided that the listserv would allow member-to-member communication. Dr. Einstein noted his goal to share this history to highlight the fact that past efforts to monitor and moderate contact ultimately failed.

Ms. Curtis cited arguments on the listserv that caused at least one member to opt out and suggested the resource was not being utilized in the manner intended. Dr. Novetsky asked if moderation mattered from a legal perspective, and Ms. Curtis noted that, per her discussion with an attorney, ASCCP would be liable in the event of a lawsuit, regardless of moderation. Dr. Novetsky followed up with a question on whether individuals would be indemnified or could be held responsible for giving an opinion. Ms. Price noted that this issue was discussed by the practice committee, with some members concluding that they would not respond even to refer to the guidelines given the potential liability.

Dr. Erin Nelson asked if responses could be reviewed before they were shared, and Dr. Einstein surmised that this would approximate the previous moderation model that left volunteer moderators overwhelmed. Dr. Novetsky asked if the listserv should be discontinued while Dr. Chelmow suggested changing the format to a web-based forum, allowing misinformation to be easily deleted. Dr. Downs noted discussion with staff about revising the listserv as a forum solely for information to be shared, but suggested that would differ little from the current iteration. He suggested considering whether there were enough members that benefit from the service to outweigh the issues. Dr. Flowers noted a comment from Dr. Lindsay Kuroki in the chat: *"Just wanted to highlight that a prior membership survey reflected that members really wanted 'access to experts' and considered it a perk to ASCCP membership."* Ms. Curtis highlighted an additional comment from Dr. Amy Wiser that *"'access to experts' vs a 'listserv of peers' are two different concepts."* Dr. Novetsky asked for analytics on unique posters, noting that 20 unique posters vs 200 changes the conversation, and Ms. Price indicated that there were 44 questions posted to the listserv last year.

In response to a question from Dr. Flowers about derogatory responses on the listserv, Ms. Price indicated that the arguments were among those offering responses, not directed toward original posters, and highlighted an instance with an argument between two well-known ASCCP members. Dr. Chelmow suggested that two knowledgeable people disagreeing on a topic not covered in the guidelines is perhaps what the service exists for. **Dr. Flowers asked**

staff to compile examples of these issues on the listserv for the EC to review, assess, and bring back to the board with a recommendation. Ms. Patty Cason asked if the concerns were about liability, misinformation or unprofessionalism, and Dr. Flowers suggested all were of concern and reiterated the need for the EC to review and summarize the concerns and present its recommendation to the board.

VII NEW BUSINESS

a. Strategic Planning

Dr. Flowers noted that the solid financial position of the society afforded the opportunity to pursue new strategic objectives. She referred the board to pp. 32-37 in the board book and walked through the objectives derived from the strategic planning meeting, along with timelines and responsible parties assigned to each. She noted that the total projected budget of approximately 600k covered all tasks outlined in the plan over the entire timeline, rather than a one-time outlay.

Dr. Downs made a motion to approve the objectives, timeline, and potential budget outlined in the strategic plan outline. In response to a question from Dr. Chelmow, Dr. Flowers confirmed that this vote constituted approval of the objectives and tasks outlined and recognition of the proposed budget but not a specific approval of the release of funds. Dr. Khan asked how often this list would be reassessed, and Dr. Flowers surmised the objectives would be revisited at every board meeting. Ms. Curtis added that in the past, staff typically would outline a task list that would be tied to the objectives on the strategic plan. To Dr. Chelmow's question, Ms. Curtis indicated that the approval was not for the release of funds but for the goals, tasks, and timeline outlined.

Dr. Chelmow moved that the board approve the strategic plan and timeline with the understanding that the financial decisions would be made on a case-by-case basis, and Dr. Khan seconded with the stipulation that the board reassess the timeline quarterly.

Dr. Einstein noted that the development committee might be tasked with fundraising for some of these objectives. Ms. Curtis indicated that she intended to work within the operating budget of each year to cover costs and only dip into reserves if needed, and agreed that this would be discussed every quarter.

b. Cervical Cancer in Immunocompromised—Update

Dr. Flowers noted that Anna-Barbara Moscicki worked on the original paper on this topic, now in need of an update. Dr. Moscicki will lead the charge on the update and has reached out to members who participated in the writing of the original paper to participate as well as a medical oncologist.

Dr. Chelmow recused himself from the discussion of the USPSTF Anal Cancer Screening Draft Research Plan and left the meeting.

c. USPSTF—Anal Cancer

Dr. Flowers indicated that the USPSTF Anal Cancer Screening Draft Research Plan was open for comment and she and other members of the board who were involved as investigators on the ANCHOR trial took the initiative to provide responses to the draft plan. These responses, Dr.

Flowers noted, were reviewed and approved by the EC and then submitted by Ms. Curtis last week. Dr. Flowers reviewed each of the responses found on pp. 38-50.

In response to a question from Dr. Kuroki about whether the USPSTF guidelines would ultimately be considered for publication in the JLGTD, Dr. Flowers indicated that the ANCHOR investigators weren't part of the process but would love to publish in the journal. Dr. Garcia suggested that this feedback was both important and substantive and would be considered by USPSTF and Dr. Flowers expressed her appreciation for all who were part of the process.

VIII CLOSING REMARKS

The next board meeting will take place in person on Thursday, May 4, 2023 at the Marriott Marquis Houston in Houston, TX.

Ms. Curtis reminded all to connect with Liesl Robinson regarding travel.

IX ADJOURNMENT

The meeting was adjourned at 8:08 pm ET.